Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Amazon Explores AI Content Marketplace With Media Publishers 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
COLUMBIA, Md., Nov. 13, 2017 -- WellDoc®, a leading digital health company, announced today that IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar®, WellDoc’s FDA-cleared, proven digital therapeutic for people living with type 2 diabetes, the “top app” in the category of clinical diabetes treatment. The related report entitled, “The Growing Value of Digital Health: Evidence and Impact on Human Health and the Healthcare System,” featured the top-rated apps for patients to manage conditions including cancer, diabetes, hypertension and asthma.
“It’s an honor to have IQVIA name BlueStar as the top app in the category of clinical diabetes treatment,” said WellDoc’s CEO Kevin McRaith. “IQVIA, who we’ve known for years as Quintiles/IMS, is a leading global provider of information that focuses on using data and science to help healthcare clients find better solutions for their patients.”
IQVIA rated the apps via scores calculated using a proprietary system that takes into account many factors including: approvals by healthcare providers, patient ratings, endorsements from regulators and clinicians, and peer-reviewed articles.
The IQVIA report concluded that strong evidence now exists for the use of digital health in diabetes, depression and anxiety, making these categories strong candidates for consideration by clinical guideline writers. To learn more, visit www.IQVIA.com.
About WellDoc®
WellDoc® is the leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model, and our foundation is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes. Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. For more information, visit www.welldoc.com.
Media Contact:
Juliette Bogus
PressComm PR
Tel: +410.980.5687
Email: [email protected]
